Abstract:
Methods are described for producing enteroendocrine cells that make and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo proteins or biologically active fragments or variants thereof.
Abstract:
The present invention provides a method of more efficiently producing pancreas cells, particularly pancreatic hormone-producing cells, a method of stably producing pancreas cells in a large amount by more efficiently inducing differentiation of stem cells into pancreas cells, a medicament containing a pancreas cells and a screening method using the cells. A method of producing pancreatic hormone-producing cells, including subjecting stem cells to the following steps (1) - (4): (1) a step of cultivating stem cells in a medium containing an activator of activin receptor-like kinase-4,7 and a GSK3 inhibitor (2) a step of cultivating the cells obtained in the aforementioned step (1) in a medium containing an activator of activin receptor-like kinase-4,7 (3) a step of cultivating the cells obtained in the aforementioned step (2) in a medium containing any one or more kinds selected from the group consisting of (a) retinoic acid receptor agonists, (b) at least one kind selected from the group consisting of inhibitors of AMP-activated protein kinase and/or activin receptor-like kinase-2,3,6, and BMP antagonists, and (c) inhibitors of activin receptor-like kinase-4,5,7 (4) a step of cultivating the cells obtained in the aforementioned stem (3).
Abstract:
This disclosure relates to pancreatic stromal progenitor cells. This disclosure also relates to isolation of pancreatic stromal progenitor cells. This disclosure further relates to a composition comprising pancreatic stromal progenitor cells and preparation of this composition. This disclosure also relates to a treatment comprising administering a composition comprising pancreatic stromal progenitor cells. This disclosure also relates to a treatment of diabetes mellitus comprising administering a composition comprising pancreatic stromal progenitor cells.
Abstract:
Disclosed is a use of a SUSD2 protein as a marker, in particular a use of the SUSD2 protein as the marker in identification, selection or separation of pancreatic internal secretion precursor cells and/or newborn pancreatic internal secretion cells; and a use of an mRNA, for encoding the SUSD2 protein, of a precursor protein as the marker in identification of the pancreatic internal secretion precursor cells and/or the newborn pancreatic internal secretion cells. Through analysis of gene expression of pancreatic endoderm cells sourced by induced directional differentiation of human pluripotent stem cells, the enrichment expression of a SUSD2 gene in the pancreatic internal secretion precursor cells and the newborn pancreatic internal secretion cells is found. In addition, a protein encoded by the SUSD2 gene is a receptor protein on cell membranes. Using the protein as the marker, the identification, the selection or the separation of the pancreatic internal secretion precursor cells and the newborn pancreatic internal secretion cells can be carried out, which has an important significance on research about pancreas related cells in each development stage.
Abstract:
Disclosed herein is a method for differentiating PDX1-positive pancreatic progenitor cells into NKX6.1 positive pancreatic progenitor cells with a culture medium comprising a) KGF and b) SANT1, wherein the culture medium is substantially free of (1) a Protein Kinase C (PKC) Activator or (2) a BMP signaling pathway inhibitor.
Abstract:
A decellularized or synthetic tissue matrix comprising specific human placental stem cells, and their uses in method for repairing or replacing tissue in a patient.
Abstract:
The invention relates to genetically modified human pancreatic progenitor cells, comprising an exogenous nucleic acid molecule encoding TGIF2, for use as a medicament in the treatment of a subject with diabetes, in addition to methods for the production of said cells. The invention also comprises an expression vector encoding TGIF2 for use as a medicament in the treatment of a subject with diabetes.
Abstract:
A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
Abstract:
The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of pancreatic endoderm cells, wherein the initial seeding density of undifferentiated epluripotent cells is defined.
Abstract:
The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.